At BMEM Bio, our mission has always been to make human pluripotent stem cell (hPSC) research more affordable, scalable, and accessible to every lab, from academic groups to biotech companies driving cell therapy innovation.
Today, we’re excited to announce the release of our latest white paper, titled “Synthemax as a cost-effective alternative to Matrigel.”
This publication explores how Synthemax, a defined, xeno-free substrate, can serve as a reliable and economical replacement for Matrigel, one of the most widely used and costly extracellular matrices in iPSC culture.
The white paper provides:
Direct performance comparisons between Synthemax and Matrigel in maintaining pluripotency and supporting iPSC attachment and expansion.
Cost analyses demonstrating how labs can significantly reduce consumable expenses without sacrificing culture quality.
Practical guidance on transitioning from Matrigel to Synthemax for routine iPSC maintenance and differentiation workflows.
By publishing this resource, BMEM Bio aims to empower scientists and organizations to optimize their stem cell workflows while maintaining compliance with chemically defined, animal origin–free standards.
📄 Read the full white paper here: Synthemax as a cost-effective alternative to Matrigel
At BMEM Bio, we believe cost should never be a barrier to advancing stem cell science. This white paper reflects our continued commitment to helping researchers do more, without compromising quality or reproducibility.